12 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $323M | -$61M | 40.6% | -28.2% | -$124M | — | $50M |
| 2024 | $283M | -$43M | 37.8% | -26.1% | -$19M | — | $55M |
| 2023 | $289M | -$168M | 36.1% | -67.6% | $5M | — | $97M |
| 2022 | $619M | $143M | 59.3% | 28.8% | $235M | — | $80M |
| 2021 | $993M | $507M | 78.3% | 68.1% | $515M | — | $165M |
| 2020 | $422M | $214M | 78.7% | 68.8% | $105M | — | $87M |
| 2019 | $33M | -$411000 | 56.6% | -1.3% | $4M | — | $12M |
| 2018 | $21M | -$6M | 49.9% | -23.7% | -$3M | — | $7M |
| 2017 | $19M | -$3M | 54.3% | -18.6% | -$2M | — | $6M |
| 2016 | — | -$5M | — | — | $617000 | — | $8M |
| 2015 | — | -$8M | — | — | -$3M | — | $489000 |
| 2014 | — | -$4M | — | — | -$5M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $71M | -$25M | 30.2% | -48.7% | $2M | — | $23M |
| Dec '25 | $83M | -$23M | 39.1% | -43.5% | -$83M | — | $50M |
| Sep '25 | $84M | -$7M | 42.2% | -18.3% | $5M | — | $118M |
| Jun '25 | $82M | -$19M | 42.1% | -24.1% | -$37M | — | $88M |
| Mar '25 | $73M | -$12M | 38.6% | -26.9% | -$9M | — | $67M |
| Dec '24 | $76M | -$6M | 41.8% | -21.2% | $21M | — | $55M |
| Sep '24 | $72M | -$15M | 37.3% | -23.8% | -$35M | — | $58M |
| Jun '24 | $71M | -$9M | 37.3% | -26.6% | -$9M | — | $65M |
| Mar '24 | $64M | -$13M | 34.3% | -33.8% | $3M | — | $55M |
| Dec '23 | $71M | -$128M | 35.8% | -214.3% | $12M | — | $97M |
| Sep '23 | $85M | -$13M | 47.0% | 0.3% | $5M | — | $84M |
| Jun '23 | $68M | -$11M | 30.3% | -29.2% | -$2M | — | $58M |
| Mar '23 | $66M | -$15M | 28.4% | -37.5% | -$10M | — | $66M |
| Dec '22 | $68M | -$24M | 19.2% | -54.0% | $28M | — | $80M |
| Sep '22 | $106M | $2M | 43.6% | 0.3% | $15M | — | $169M |
| Jun '22 | $125M | $12M | 52.1% | 10.2% | $8M | — | $139M |
| Mar '22 | $320M | $154M | 75.7% | 63.1% | $183M | — | $353M |
| Dec '21 | $252M | $104M | 75.3% | 59.9% | $71M | — | $165M |
| Sep '21 | $228M | $123M | 80.9% | 69.9% | $149M | — | $215M |
| Jun '21 | $154M | $80M | 76.7% | 64.4% | $73M | — | $100M |
How the market has priced FLGT against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Fulgent Genetics, Inc.'s revenue has declined 5.2% per year. These are computed facts, not advice.
As of FY2025, Fulgent Genetics, Inc. reported — of total debt against $50M of cash; operating income covered interest expense -1214.6×.
In FY2025, gross margin was 40.6%, operating margin -28.2%, and net margin -18.8%.
As of Jun '26, Fulgent Genetics, Inc. traded at a price-to-earnings ratio of about 5.7× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.